Nordson Corporation (NDSN)
POSITIVEFondamental
70
Prix
$334.96
Capitalisation boursière
$18.51B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Nordson makes precision dispensing equipment: machines that apply exact, controlled amounts of adhesives, coatings, sealants and other fluids inside a factory line, plus components used in medical devices and semiconductor manufacturing. Its products are typically a small line item inside a much larger production process — a diaper plant's glue applicator, a chip packaging step, a catheter's plastic tubing — but a failure or imprecision there can shut the whole line down.
Comment l'entreprise gagne de l'argent
Revenue comes mostly from selling dispensing systems and components once, plus recurring sales of spare parts, nozzles and service that keep those systems running precisely over years of use. Because customers integrate Nordson's equipment into a validated production process, replacing it later requires re-qualifying the whole line, which supports steady repeat business rather than one-off equipment sales.
Chiffre d'affaires par segment
Adhesive, coating and sealant dispensing systems sold into packaging, general industrial and consumer goods production lines.
Components and precision fluid-management systems used in medical devices such as catheters, plus fluid dispensing for other industries.
Equipment used in semiconductor and electronics manufacturing, including chip packaging and testing steps.
Avantage concurrentiel
Coûts de changement · ÉtroitOnce a customer validates a production line around Nordson's dispensing equipment — calibrated to exact fluid volumes and tolerances, sometimes under regulatory approval as in medical devices — swapping to a competitor means re-validating the whole line, a costly and slow process manufacturers avoid unless something is badly wrong. That keeps replacement parts and service revenue sticky even where the original equipment sale was competitive.
Ce qui stimule la demande
Modérément cycliqueDemand splits between steadier end markets — packaging, medical devices, consumer nondurables — and more cyclical ones like semiconductor and electronics capital spending, which swings with chip industry investment cycles. The mix of the three segments smooths some of that cyclicality but does not remove it, particularly in the Advanced Technology segment.
Principaux risques
- Cyclicality in semiconductor capital spending — The Advanced Technology Solutions segment depends on chip makers' capital equipment budgets, which are historically volatile and can swing sharply between shortage and oversupply periods.
- Acquisition integration risk — Nordson has grown its segments partly through acquisitions; integrating acquired businesses' operations, systems and customer relationships carries execution risk and can strain expected returns.
- Customer capital spending decisions — Equipment sales depend on customers deciding to build or upgrade production lines, decisions that can be postponed in an uncertain economic environment even when replacement parts demand continues.
- International operations and currency exposure — A significant share of sales and manufacturing occurs outside the United States, exposing results to currency translation and to economic and trade conditions in those markets.
Les arguments en faveur
Buyers argue that Nordson's equipment gets embedded in validated production lines across three diversified end markets, that recurring parts and service revenue smooths the cycle, and that record fiscal 2025 results show the model compounding through both steadier and more cyclical segments at once.
Les arguments contre
Sellers fear that the Advanced Technology segment remains exposed to a genuinely volatile semiconductor capital-spending cycle, that growth built partly through acquisitions carries integration risk that can disappoint, and that a broader industrial slowdown would delay the equipment upgrades that drive the larger, steadier segments too.
Written by the editors, published on 18 août 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$2.98B
12 derniers mois (au 31/07/2026)
Résultat net
$555M
12 derniers mois (au 31/07/2026)
Flux de trésorerie libre
$661M
Capitaux propres totaux
$3.04B
Passif total
$2.87B
Ratio de liquidité général
1.82
Couverture des intérêts
8.83
Dette/EBITDA
2.30
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$291.28
Prix actuel
$334.96
Marge de sécurité
-15.0%
Fourchette de juste valeur
$219.91 - $362.64
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
33.83
ROE
15.9%
Ratio P/B
5.69
P/FCF
25.69
Marge brute
55.3%
ROIC
12.1%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
12.1%
WACC
9.5%
ROIC − WACC
+2.6 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critères d'analyse fondamentale
Réussi (21)
- EPS shows upward trend
- EPS CAGR 5.49%
- Price CAGR 11.48%
- ROIC 12.1%
- Gross Margin 55.3%
- P/FCF 25.69
- Debt/Equity ratio
- Operating Margin 26.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 17.1%
- Revenue Growth 5Y 5.7%
- Analyst Consensus 67% Buy
- Earnings Quality (OCF/NI) 1.39
- Share Dilution -1.2%
- Net Margin Trend 18.6% vs 16.3%
- Piotroski F-Score 7/9
Échoué (6)
- P/B Ratio 5.69
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.3%
- PEG Ratio 2.19
Indisponible (1)
- Dividend Payout NaN%
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Sundaram Nagarajan | President, CEO & Director | 62 |
| Mr. Daniel R. Hopgood | Executive VP & CFO | 52 |
| Ms. Jennifer L. McDonough J.D. | Executive VP, General Counsel & Corporate Secretary | 53 |
| Mr. Joseph P. Kelley | Executive VP of Industrial Precision Solutions Leader | 52 |
| Mr. Joseph M. Rutledge | VP & Chief Accounting Officer | 45 |
| Ms. Lara L. Mahoney | Vice President of Investor Relations & Corporate Communications | - |
| Katie Colacarro | Vice President of Corporate Development | - |
| Ms. Sarah Siddiqui | Executive VP & Chief Human Resources Officer | 47 |
| Mr. Justin Hall | Executive Vice President of Medical & Fluid Solutions | 46 |
Risque d'audit
9
Risque du conseil
3
Risque de rémunération
6
Risque droits des actionnaires
10
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for NDSN, sourced from Markets Gazette.
- 4d agoPOSITIVEThursday’s Activity, 4 Possible Friday Plays
Nordson Corporation (NDSN) was highlighted as a potential multi-bagger opportunity in Thursday's trading session, with the NDSN Weekly $310-320 call options showing significant upside potential. The article suggests that the stock has delivered strong performance, aligning with the firm's successful track record of identifying profitable trading plays. Investors who followed this recommendation may have seen substantial gains, indicating positive momentum for the company's stock.
via Markets Gazette